http://publicationslist.org/data/emiliano.calvo/atom.xml Emiliano Calvohttp://publicationslist.org/emiliano.calvo$basepathfavicon.icoRecent additions to Emiliano Calvo's PublicationsList.org pagehttp://publicationslist.org/publications.png2010-11-25T07:36:00Z http://publicationslist.org/emiliano.calvo/refid10 2010-11-24T22:13:57Z

BACKGROUND: Maximum tolerated dose (MTD) chemotherapy followed by metronomic chemotherapy (low doses given on a frequent schedule) acts on tumour vascular endothelial cells by increasing the anti-tumour effect of anti-angiogenic agents. This multicentre, phase 2 study investigated the effectiveness of MTD gemcitabine combined with metronomic capecitabine plus the multikinase inhibitor sorafenib fo...<br/><br/>Joaquim Bellmunt, José Manuel Trigo, Emiliano Calvo, Joan Carles, José L Pérez-Gracia, Jordi Rubió, Juan Antonio Virizuela, Rafael López, Martín Lázaro, Joan Albanell (2010) <i>Lancet Oncol</i> <i></i> <i></i> 11: 4 350-357<br/>

http://publicationslist.org/emiliano.calvo/refid8 2010-11-24T22:13:57Z

Elderly or frail patients are often excluded from clinical trials. As a result, clinical outcome of these patients may differ from those obtained in trials. This situation may also hold true for patients who have severe concomitant diseases such as renal, hepatic, or cardiac dysfunction. Being aware of the wide range of clinical situations that a specialist may face is important to ensure that und...<br/><br/>Emiliano Calvo, Pablo Maroto, Xavier García del Muro, Miguel Angel Climent, José Luis González-Larriba, Emilio Esteban, Rafael López, Luis Paz-Ares, Joaquim Bellmunt, Daniel Castellano (2010) <i>Cancer Metastasis Rev</i> <i></i> <i></i> 29 Suppl 1: 11-20<br/>

http://publicationslist.org/emiliano.calvo/refid9 2010-11-24T22:13:57Z

RATIONALE: Noninfectious pneumonitis is a known class effect of mammalian target of rapamycin (mTOR) inhibitors. Objectives: To assess the incidence, radiographic patterns, management, and outcome of pneumonitis in patients with advanced renal cell carcinoma receiving everolimus. METHODS: Clinical study data from 416 patients, randomized to receive everolimus versus placebo, were analyzed for adve...<br/><br/>Dorothy A White, Philippe Camus, Masahiro Endo, Bernard Escudier, Emiliano Calvo, Hideyuki Akaza, Hirotsugu Uemura, Euloge Kpamegan, Andrea Kay, Matthew Robson, Alain Ravaud, Robert J Motzer (2010) <i>Am J Respir Crit Care Med</i> <i></i> <i></i> 182: 3 396-403<br/>

http://publicationslist.org/emiliano.calvo/refid7 2010-11-24T22:13:57Z

The speed at which targeted therapies are being developed and incorporated into the treatment of advanced renal cell carcinoma (RCC) is surprising. After decades in which the only systemic treatment options available for advanced disease were interleukin-2 and interferon-alpha, in the last decade, six new targeted therapies have emerged showing meaningful clinical benefits to patients with advance...<br/><br/>Emiliano Calvo, Pablo Maroto, Xavier García del Muro, Miguel Angel Climent, José Luis González-Larriba, Emilio Esteban, Rafael López, Luis Paz-Ares, Joaquim Bellmunt, Daniel Castellano (2010) <i>Cancer Metastasis Rev</i> <i></i> <i></i> 29 Suppl 1: 1-10<br/>

http://publicationslist.org/emiliano.calvo/refid14 2010-11-24T23:18:40Z

The prominence of the PI3K-Akt signaling pathway in several tumors indicates a relationship with tumor grade and proliferation. Critical cellular processes are driven through this pathway. More detailed knowledge of the pathogenesis of tumors would enable us to design targeted drugs to block both membrane tyrosine kinase receptors and the intracellular kinases involved in the transmission of the s...<br/><br/>Emiliano Calvo, Victoria Bolós, Enrique Grande (2009) <i>Onco Targets Ther</i> <i></i> <i></i> 2: 135-150<br/>

http://publicationslist.org/emiliano.calvo/refid15 2010-11-24T22:13:57Z

BACKGROUND: Complex interrelationships exist between the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) receptor pathways. EGFR activation elicits cell proliferation and increased VEGF expression. To maximally inhibit EGFR and then downstream VEGF activity, this phase I study was initiated to determine the maximum tolerated dose (MTD) of erlotinib with fixed-...<br/><br/>Chia-Chi Lin, Emiliano Calvo, Kyriakos P Papadopoulos, Amita Patnaik, John Sarantopoulos, Alain C Mita, Glenn G Preston, Monica M Mita, Jordi Rodon, Theresa Mays, I-Tien Yeh, Pat O'Rourke, Chris H Takimoto, Janet E Dancey, Helen Chen, Anthony W Tolcher (2009) <i>Cancer Chemother Pharmacol</i> <i></i> <i></i> 63: 6 1065-1071<br/>

http://publicationslist.org/emiliano.calvo/refid13 2010-11-24T22:13:57Z

OBJECTIVES: The thioxanthone analog, SR271425, is a novel cytotoxic DNA-interacting agent with broad antitumor activity in preclinical models. The objectives of this phase I study were to determine the dose-limiting toxicities, maximum tolerated dose, recommended phase II dose, pharmacokinetic profile, and trend for efficacy in patients with advanced cancer. METHODS: SR271425 was administered intr...<br/><br/>A Craig Lockhart, Emiliano Calvo, Anthony W Tolcher, Eric K Rowinsky, Gareth Shackleton, J Gilmour Morrison, Rezvan Rafi, Wendy VerMeulen, Mace L Rothenberg (2009) <i>Am J Clin Oncol</i> <i></i> <i></i> 32: 1 9-14<br/>

http://publicationslist.org/emiliano.calvo/refid12 2010-11-24T22:13:57Z

For almost the last two decades, interleukin-2 and interferon-alpha have been the only systemic treatment options available for metastatic renal cell carcinoma. However, in recent years, five new targeted therapies namely sunitinib, sorafenib, temsirolimus, everolimus and bevacizumab have demonstrated clinical activity in these patients. With the availability of new targeted agents that are active...<br/><br/>Joaquim Bellmunt, Emiliano Calvo, Daniel Castellano, Miguel Angel Climent, Emilio Esteban, Xavier García del Muro, José Luis González-Larriba, Pablo Maroto, José Manuel Trigo (2009) <i>Cancer Chemother Pharmacol</i> <i></i> <i></i> 63 Suppl 1: S1-13<br/>

http://publicationslist.org/emiliano.calvo/refid11 2010-11-24T22:13:57Z

PURPOSE: The study aimed to assess the pharmacokinetic behavior of satraplatin under fasted and fed conditions, and its safety and preliminary antitumor activity in adults with advanced solid tumors. EXPERIMENTAL DESIGN: Satraplatin was administered orally at 80 mg/m(2) once daily with prophylactic antiemetics for 5 consecutive days every 5 weeks. Patients were randomized to receive day 1 and day ...<br/><br/>Alejandro D Ricart, John Sarantopoulos, Emiliano Calvo, Quincy S Chu, Douglas Greene, Faith E Nathan, Michael E Petrone, Anthony W Tolcher, Kyriakos P Papadopoulos (2009) <i>Clin Cancer Res</i> <i></i> <i></i> 15: 11 3866-3871<br/>

http://publicationslist.org/emiliano.calvo/refid17 2010-11-24T22:14:46Z

PURPOSE: Everolimus is a selective mammalian target of rapamycin (mTOR) inhibitor with promising anticancer activity. In order to identify a rationally based dose and schedule for cancer treatment, we have conducted a tumor pharmacodynamic phase I study in patients with advanced solid tumors. PATIENTS AND METHODS: Fifty-five patients were treated with everolimus in cohorts of 20, 50, and 70 mg wee...<br/><br/>Josep Tabernero, Federico Rojo, Emiliano Calvo, Howard Burris, Ian Judson, Katharine Hazell, Erika Martinelli, Santiago Ramon y Cajal, Suzanne Jones, Laura Vidal, Nicholas Shand, Teresa Macarulla, Francisco Javier Ramos, Sasa Dimitrijevic, Ulrike Zoellner, Pui Tang, Michael Stumm, Heidi A Lane, David Lebwohl, José Baselga (2008) <i>J Clin Oncol</i> <i></i> <i></i> 26: 10 1603-1610<br/>

http://publicationslist.org/emiliano.calvo/refid16 2010-11-24T23:16:38Z

Aleix Prat, César Serrano, Claudia Valverde, Emiliano Calvo (2008) <i>Radiother Oncol</i> <i></i> <i></i> 89: 1 124-125<br/>

http://publicationslist.org/emiliano.calvo/refid36 2010-11-24T23:15:49Z

BACKGROUND: The purpose of the study was to evaluate the effects of erlotinib on epidermal growth factor receptor (EGFR)-related signaling elements in tumor and skin from patients with advanced squamous cell carcinoma of the head and neck (HNSCC) and seek relationships between relevant clinical, biological, and pharmacokinetic parameters. PATIENTS AND METHODS: Immunostaining for EGFR, p-EGFR, p-ER...<br/><br/>E Calvo, S N Malik, L L Siu, G M Baillargeon, J Irish, S F Chin, P Santabarbara, J I Kreisberg, E K Rowinsky, M Hidalgo (2007) <i>Ann Oncol</i> <i></i> <i></i> 18: 4 761-767<br/>

http://publicationslist.org/emiliano.calvo/refid18 2010-11-24T22:14:46Z

The success of the taxanes and other agents that target tubulin and mitosis and their evolution to being mainstay constituents of both curative and palliative therapeutic regimens for a wide variety of malignancies have amplified efforts to discover anti-mitotic and anti-microtubule agents with greater therapeutic indices. A wide variety of structurally diverse compounds that have demonstrated bro...<br/><br/>Eric K Rowinsky, Emiliano Calvo (2006) <i>Semin Oncol</i> <i></i> <i></i> 33: 4 421-435<br/>

http://publicationslist.org/emiliano.calvo/refid19 2010-11-24T22:14:46Z

The identification of somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) in non-small-cell lung cancer (NSCLC) and their correlation with response to EGFR inhibitors has become an important event in the fields of cancer genetics and therapeutics. The initial observation of a higher response to gefitinib and erlotinib in patients of Asian origin was follo...<br/><br/>Emiliano Calvo, José Baselga (2006) <i>J Clin Oncol</i> <i></i> <i></i> 24: 14 2158-2163<br/>

http://publicationslist.org/emiliano.calvo/refid35 2010-11-24T23:14:53Z

Testicular germ cell tumors (TCGT) comprise a heterogeneous group of neoplasms, although all of them are originated from common precursors related to germ cell lineage. Understanding of normal development of germinal cells is essential to define new markers for diagnosis, prognostic subgroups and targeted therapies. Recent advances related to cytogenetic and molecular features have established the...<br/><br/>E Vilar, E Calvo, J Tabernero (2006) <i>Clin Transl Oncol</i> <i></i> <i></i> 8: 12 846-850<br/>

http://publicationslist.org/emiliano.calvo/refid32 2010-11-24T23:08:17Z

I Gil-Bazo, J-A Díaz-González, J Rodríguez, J Cortés, E Calvo, J-A Páramo, J García-Foncillas (2005) <i>World J Gastroenterol</i> <i></i> <i></i> 11: 38 6072-6073<br/>

http://publicationslist.org/emiliano.calvo/refid21 2010-11-24T22:14:46Z

Recent knowledge about the intermediate steps and final consequences of ligand-dependent epidermal growth factor receptor (EGFR) activation has clearly supported the notion that EGFR plays a fundamental role in regulating the proliferation and survival of malignant neoplasms. Among the rationally designed target-based therapeutics that are being assessed, those targeting EGFR appear to be some of ...<br/><br/>Emiliano Calvo, Eric K Rowinsky (2005) <i>Curr Oncol Rep</i> <i></i> <i></i> 7: 2 96-103<br/>

http://publicationslist.org/emiliano.calvo/refid20 2010-11-24T22:14:46Z

Preclinical and clinical studies consistently demonstrate the antitumor activity of the various monoclonal antibodies (mAbs) that block ligand binding to the extracellular domain of the epidermal growth factor receptor (EGFR). However, the objective antitumor activities of these agents are disproportionately lower than would be expected based on the high rates of expression, overexpression, and ab...<br/><br/>Emiliano Calvo, Eric K Rowinsky (2005) <i>Curr Oncol Rep</i> <i></i> <i></i> 7: 2 123-128<br/>

http://publicationslist.org/emiliano.calvo/refid23 2010-11-24T22:14:46Z

PURPOSE: To determine the maximum tolerated dose of administrating CI-1033, an oral 4-anilinoquinazoline that irreversibly inhibits the tyrosine kinase domain of all erbB subfamilies, on an intermittent schedule, and assess the interaction of CI-1033 with food on the pharmacokinetic behavior. EXPERIMENTAL DESIGN: Escalating doses of CI-1033 from a dose level of 300 mg/day for 7 days every other we...<br/><br/>Emiliano Calvo, Anthony W Tolcher, Lisa A Hammond, Amita Patnaik, Johan S de Bono, Irene A Eiseman, Stephen C Olson, Peter F Lenehan, Heather McCreery, Patricia Lorusso, Eric K Rowinsky (2004) <i>Clin Cancer Res</i> <i></i> <i></i> 10: 21 7112-7120<br/>

http://publicationslist.org/emiliano.calvo/refid22 2010-11-24T22:14:46Z

The recent identification of somatic mutations in the epidermal growth factor receptor (EGFR)-tyrosine kinase (TK) domain of tumor samples from patients with non-small-cell lung cancer (NSCLC) that portend robust response to small-molecule inhibitors of EGFR TK is a watershed event in the fields of lung cancer genetics and therapeutic agents. In addition to paralleling what is already known about ...<br/><br/>Emiliano Calvo, Eric K Rowinsky (2004) <i>Clin Lung Cancer</i> <i></i> <i></i> 6 Suppl 1: S35-S42<br/>

http://publicationslist.org/emiliano.calvo/refid24 2010-11-24T22:14:46Z

Vinorelbine-cisplatin combination chemotherapy is a standard approach for the treatment of advanced non-small-cell lung cancer (NSCLC). The addition of paclitaxel as a third therapeutic agent seems promising. The aim of the present study was to evaluate the activity and toxicity of this new regimen. Forty-six nonselected and chemotherapy-naive patients with stage IV NSCLC and an Eastern Cooperativ...<br/><br/>Javier Cortes, Javier Rodriguez, Emiliano Calvo, Alfonso Gurpide, Jesus Garcia-Foncillas, Esteban Salgado, Jose Manuel Aramendia, Jose Maria Lopez-Picazo, Berta Hernandez, Rebeca Hidalgo, Jose Javier Aristu, Antonio Brugarolas, Salvador Martin-Algarra (2004) <i>Am J Clin Oncol</i> <i></i> <i></i> 27: 3 299-303<br/>

http://publicationslist.org/emiliano.calvo/refid1 2010-11-24T22:12:55Z

OBJECTIVE: Paclitaxel-cisplatin is considered to be a standard therapy for metastatic non-small-cell lung cancer (NSCLC). The aim of this study was to evaluate the activity and toxicity of this combination with vinorelbine or gemcitabine as front-line therapy in brain metastases from NSCLC. METHODS: Twenty-six chemotherapy-naive patients with an ECOG performance status of 0-2 were treated with pac...<br/><br/>Javier Cortes, Javier Rodriguez, Jose Manuel Aramendia, Esteban Salgado, Alfonso Gurpide, Jesus Garcia-Foncillas, Jose Javier Aristu, Angela Claver, Ana Bosch, Jose Maria Lopez-Picazo, Salvador Martin-Algarra, Antonio Brugarolas, Emiliano Calvo (2003) <i>Oncology</i> <i></i> <i></i> 64: 1 28-35<br/>

http://publicationslist.org/emiliano.calvo/refid25 2010-11-24T22:14:46Z

Emiliano Calvo, Manuel Sureda (2003) <i>Lancet</i> <i></i> <i></i> 361: 9370 <br/>

http://publicationslist.org/emiliano.calvo/refid6 2010-11-24T22:12:55Z

Emiliano Calvo, Francisco Fernández-La Torre, Antonio Brugarolas (2002) <i>J Natl Cancer Inst</i> <i></i> <i></i> 94: 15 1175-1176<br/>

http://publicationslist.org/emiliano.calvo/refid5 2010-11-24T22:12:55Z

Emiliano Calvo, Francisco José Fernández, Jerónimo Forteza, Antonio Brugarolas (2002) <i>Med Clin (Barc)</i> <i></i> <i></i> 119: 10 396-397<br/>

http://publicationslist.org/emiliano.calvo/refid33 2010-11-24T23:08:17Z

Tumour response evaluation after chemotherapy has become crucial in the development of many drugs. In contrast to the standard bidimensional WHO criteria, the recently described Response Evaluation Criteria In Solid Tumors are based on unidimensional measurements. The aim of the present study was to compare both methods in patients with metastatic non-small cell lung cancer. One hundred and sixty-...<br/><br/>J Cortes, J Rodriguez, J A Diaz-Gonzalez, C Garzon, A Gurpide, L Arbea, I Gil-Bazo, V Navarro, M Cambeiro, A I Nicolas, S Martin-Algarra, J Garcia-Foncillas, E Calvo (2002) <i>Br J Cancer</i> <i></i> <i></i> 87: 2 158-160<br/>

http://publicationslist.org/emiliano.calvo/refid26 2010-11-24T22:14:46Z

Emiliano Calvo (2002) <i>Clin Colorectal Cancer</i> <i></i> <i></i> 2: 3 170-172<br/>

http://publicationslist.org/emiliano.calvo/refid2 2010-11-24T22:12:55Z

The purpose of this study was to evaluate the efficacy and tolerance of a combination of irinotecan, oxaliplatin, and 5-fluorouracil (5-FU)/leucovorin in advanced colorectal cancer (ACC). Twenty-six consecutive patients with ACC and an Eastern Cooperative Oncology Group performance status of 0-2 were treated with a combination of oxaliplatin (120 mg/m2 intravenously [i.v.] for 2 hours) on day 1, i...<br/><br/>Emiliano Calvo, Javier Cortés, Javier Rodríguez, Oscar Fernández-Hidalgo, Joseba Rebollo, Salvador Martín-Algarra, Jesús García-Foncillas, Rafael Martínez-Monge, Jokin de Irala, Antonio Brugarolas (2002) <i>Clin Colorectal Cancer</i> <i></i> <i></i> 2: 2 104-110<br/>

http://publicationslist.org/emiliano.calvo/refid4 2010-11-24T22:12:55Z

OBJECTIVES: To evaluate the feasibility and a possible activity range of combination irinotecan (CPT-11), oxaliplatin, and 5-FU in advanced colorectal cancer (ACC). PATIENTS AND METHODS: A total of 53 patients (51% chemoresistant) were treated. Twenty-eight received monthly intravenous oxaliplatin (120 mg/m2) and CPT-11 (250 mg/m2) on day 1 and a course of 5-FU; these constituted the IRI250 group....<br/><br/>Emiliano Calvo, Javier Cortés, María González-Cao, Javier Rodríguez, José Manuel Aramendía, Oscar Fernández-Hidalgo, Salvador Martín-Algarra, José Esteban Salgado, Rafael Martínez-Monge, Jokin de Irala, Antonio Brugarolas (2002) <i>Oncology</i> <i></i> <i></i> 63: 3 254-265<br/>

http://publicationslist.org/emiliano.calvo/refid3 2010-11-24T22:12:55Z

PRECIS: Administration of a combined regimen of docetaxel plus vinorelbine every 4 weeks is feasible and shows activity in heavily pretreated patients with advanced breast cancer. PURPOSE: To determine the activity and tolerance of docetaxel plus vinorelbine in heavily pretreated patients with advanced breast cancer. METHODS: Thirty-five metastatic breast cancer patients with ECOG performance stat...<br/><br/>Javier Rodríguez, Emiliano Calvo, J Cortes, Marta Santisteban, J Perez-Calvo, Rafael Martínez-Monge, Antonio Brugarolas, Oscar Fernández-Hidalgo (2002) <i>Breast Cancer Res Treat</i> <i></i> <i></i> 76: 1 47-56<br/>

http://publicationslist.org/emiliano.calvo/refid34 2010-11-24T23:08:17Z

J Cortes, J Rodriguez, E Calvo (2001) <i>N Engl J Med</i> <i></i> <i></i> 344: 9 <br/>

http://publicationslist.org/emiliano.calvo/refid27 2010-11-24T22:56:37Z

BACKGROUND: Using a fixed higher-dose schedule, the efficacy and toxicity of suramin plus hydrocortisone were assessed in patients with metastatic hormone-refractory prostate carcinoma (HRPC). METHODS: Fifty consecutive patients with HRPC (including those in whom hormonotherapy was withdrawn) and an Eastern Cooperative Oncology Group performance status of 0-2 were recruited. Treatment was comprise...<br/><br/>E Calvo, J Cortés, J Rodríguez, M Sureda, C Beltrán, J Rebollo, R Martínez-Monge, J M Berián, J de Irala, A Brugarolas (2001) <i>Cancer</i> <i></i> <i></i> 92: 9 2435-2443<br/>

http://publicationslist.org/emiliano.calvo/refid30 2010-11-24T23:05:07Z

Irinotecan (CPT-11) is an anticancer agent widely employed in the treatment of colorectal carcinoma. A simple, rapid and sensitive high-performance liquid chromatographic method for the simultaneous determination of CPT-11 and its metabolite SN-38 in plasma, and their preliminary clinical pharmacokinetics are described. Both deproteinisation of plasma specimens (100 microl) and addition of the int...<br/><br/>J Escoriaza, A Aldaz, C Castellanos, E Calvo, J Giráldez (2000) <i>J Chromatogr B Biomed Sci Appl</i> <i></i> <i></i> 740: 2 159-168<br/>

http://publicationslist.org/emiliano.calvo/refid28 2010-11-24T22:56:37Z

BACKGROUND: Cisplatin-based chemotherapy combinations improve quality of life and survival in advanced nonsmall cell lung carcinoma (NSCLC). The emergence of new active drugs might translate into more effective regimens for the treatment of this disease. METHODS: The objective of this study was to determine the feasibility, response rate, and toxicity of a paclitaxel, cisplatin, and gemcitabine co...<br/><br/>J Rodriguez, J Cortes, E Calvo, I Azinovic, O Fernandez-Hildago, R Martinez-Monge, C Garzon, J de Irala, M Martinez-Aguillo, T Ramon Y Cajal, A Brugarolas (2000) <i>Cancer</i> <i></i> <i></i> 89: 12 2622-2629<br/>

http://publicationslist.org/emiliano.calvo/refid29 2010-11-24T23:04:09Z

J M Lopez-Picazo, R Gonzalez Manzano, J M Ordoñez Tres, M M Jimenez, J P Calvo, A Brugarolas (2000) <i>Haematologica</i> <i></i> <i></i> 85: 9 1003-1004<br/>

http://publicationslist.org/emiliano.calvo/refid31 2010-11-24T23:05:07Z

5-Fluorouracil (5-FU) is an antineoplastic agent widely employed in the treatment of many types of cancer. Recent studies have proved the need for individual adjustment of 5-FU dosage based on pharmacokinetics. A simple and sensitive high-performance liquid chromatographic method for the determination of 5-FU in plasma and their preliminary clinical pharmacokinetics is described. After sample acid...<br/><br/>J Escoriaza, A Aldaz, E Calvo, J Giráldez (1999) <i>J Chromatogr B Biomed Sci Appl</i> <i></i> <i></i> 736: 1-2 97-102<br/>